Press releases
- Amneal to Participate at Upcoming Investor Conference
- Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
- Amneal Reports First Quarter 2024 Financial Results
- Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
- Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
- Amneal to Report First Quarter 2024 Results on May 3, 2024
- Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
- Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
More ▼
Key statistics
On Tuesday, Amneal Pharmaceuticals Inc (2DT:DUS) closed at 5.95, -6.30% below its 52-week high of 6.35, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.95 |
---|---|
High | 6.05 |
Low | 5.95 |
Bid | 6.00 |
Offer | 6.30 |
Previous close | 5.95 |
Average volume | 15.00 |
---|---|
Shares outstanding | 308.65m |
Free float | 120.40m |
P/E (TTM) | -- |
Market cap | 2.06bn USD |
EPS (TTM) | -0.5642 USD |
Data delayed at least 15 minutes, as of Jun 04 2024 18:30 BST.
More ▼